understanding of the mechanisms that control the endothelial response to inflammatory activation is still incomplete.
Notably, the role of endothelial Notch signaling in inflammatory activation seems to be highly context dependent: although hemizygous deletion of endothelial Notch1 predisposed for atherosclerosis development and monocyte recruitment in the L-sIDOL model, 10 endothelial-specific deletion of the canonical Notch transcription factor Rbpj in ApoE −/− mice reduced atherosclerotic plaque inflammation and leukocyte recruitment. 11 Notably, NOTCH1 augmented TNF-driven upregulation of the adhesion molecules VCAM1 (vascular cell adhesion molecule 1) and ICAM1 (intercellular adhesion molecule 1) in human endothelial cells, 12 and endothelial-specific overexpression of active Notch1 in mouse melanoma promoted a proinflammatory, dysfunctional phenotype that included enhanced VCAM1 expression. 13 In contrast, inhibition of NOTCH4 boosted the upregulation of VCAM1 in TNF-stimulated human endothelial cells, suggesting that NOTCH1 and NOTCH4 play opposing roles in the regulation of VCAM1. 14 The effect of NOTCH1 on other classes of inflammatory mediators is, however, less clear-cut, exemplified by the neutrophil-recruiting chemokines CXCL1 (chemokine [C-X-C motif] ligand 1) and CXCL8 that appear to be repressed by NOTCH1. 10, 13 Inflammatory events in endothelial cells are to a large extent driven by NF-κB signaling, 15 and it has been suggested that the activated NOTCH1 receptor fragment drives adhesion molecule expression by directly interacting with NF-κB subunits to facilitate their nuclear translocation and retention. 11 However, this mechanism does not account for the apparent selectivity with which NOTCH1 modulates the expression of inflammatory genes in endothelial cells.
A recently identified molecular event of endothelial cell activation is the NF-κB-directed activation of inflammatory enhancer regions, including BRD4 (bromodomain-containing protein 4)-dependent super enhancers essential to the transcriptional inflammatory response. 16 Enhancers have also been identified as the main regions containing functional Notch-binding sites that exert transcriptional control over long distances. 17, 18 However, it is not known whether Notch associates with inflammatory enhancers or affects inflammation at the genomic level.
We here show that endothelial NOTCH1 signaling promotes leukocyte recruitment by facilitating the activation of inflammatory enhancers supporting a distinct vascular transcription profile. Our findings demonstrate that NOTCH1 signaling is fundamentally involved in regulating the inflammatory response in endothelial cells, supporting the assumption that it may serve as a novel therapeutic target in chronic inflammatory disease.
Materials and Methods

Reagents
IL-1β, IFN-γ, TNF-α, EGF (epidermal growth factor), and bFGF (basic fibroblast growth factor) were from R&D Systems; hydrocortisone and dinitrofluorobenzene from Sigma Aldrich; fetal bovine serum, gentamicin, fungizone, L-glutamine, MCBD 131, Opti-MEM, and TRI Reagent from Thermo Fisher Scientific; trypsin-EDTA from BioWhittaker; and the DAPT (γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-lalanyl]-S-phenylglycine t-butyl ester) from EMD Chemicals.
Cell Culture
Umbilical cords were obtained from the Department of Gynecology and Obstetrics at Oslo University Hospital according to a protocol approved by the Regional Committee for Research Ethics, Health Region South, Norway (2014/298 S-05152a). Human umbilical vein endothelial cells (HUVECs) were isolated as described previously 19 and cultured on 0.1% gelatin-coated plastic in MCBD 131 medium containing 7.5% fetal bovine serum, 10 ng/mL EGF, 1 ng/mL bFGF, 1 µg/mL hydrocortisone, 50 µg/mL gentamicin, 250 ng/mL fungizone, and 1% L-glutamine. Cells were maintained at 37°C in 95% humidity/5% CO 2 atmosphere, split 1:3, and used at passage 2 to 6.
Human Biopsy Material
Formalin-fixed, paraffin-embedded samples of human appendix (appendicitis n=4, control n=2) were obtained from the diagnostic biobank at the Division of Pathology, Oslo University Hospital, and used in accordance with a protocol approved by the Regional Committee for Research Ethics, Health Region South, Norway (2014/298 S-05152a). Biopsies were scored by a senior clinical pathologist according to the degree of inflammation in the lamina propria as follows: evidence of granulocyte infiltration (+), granulocyte infiltration and loss of crypts (++), and when also including ulceration/necrosis (+++).
Immunostainings and Microscopy
All antibodies for immunostainings and working concentrations are specified in the Major Resource Table in the online-only Data Supplement. CD45 was detected by manual staining: tissue sections (4 µm thick, formalin fixed, paraffin embedded) were deparaffinized, boiled for 20 minutes in Dako target retrieval buffer pH 6.1, incubated with 5% donkey serum for 30 minutes at room temperature, incubated with primary antibodies diluted in PBS with 1.25% BSA overnight at 4°C, and then incubated with fluorescently labeled secondary antibodies for 60 minutes at 37°C. Hoechst 33258 nuclear dye (0.5 µg/mL) was used as counterstain. csNICD1, Ly6G, and CD3 were detected using the automated Ventana Discovery Ultra system, using standard deparaffinization, 80 minutes antigen retrieval in CC1 buffer, Disc inhibitor 4 (CD3) or 8 minutes (csNICD1), incubation with primary antibody (60 minutes), rabbit antibody amplification (csNICD1), rabbit anti-rat IgG Fc (clone R18-2, abcam, Ly6G only), UltraMap anti-rabbit-AP (CD3; 8 minutes), or UltraMap anti-rabbit-HRP (csNICD1; 20 minutes) followed by incubation with Fast Red (Ly6G, CD3) or rhodamine (csNICD1; 12 minutes). Ventana Discovery protocols are available on request. All reagents for automatic staining were purchased from Roche. Slides were washed in warm, soapy water and either mounted at this point or incubated with primary antibodies targeting vascular markers diluted in PBS with 1.25% BSA overnight at 4°C, proceeding with further manual staining as described above. Slides were mounted in ProLong Diamond Antifade mountant (Thermofisher). Irrelevant, concentration-matched primary antibodies were used as negative controls.
Confocal microscopy was performed using an Olympus FV1000 confocal microscope with 20× UPlanApo N. 
Image Analysis
Dermal CD3 positive cells and Ly6G positive cells were counted manually from images obtained by scanning whole sections of dinitrofluorobenzene-treated ears using a Pannoramic Midi scanner (3D Histiotech). Images were coded and counted blindfolded. Automated image analysis of csNICD1, CD45 positive cells, and VCAM1 was performed in Image J (v2.9.9-rc-41/1.50b). Endothelial csNICD1 signal was quantified in 10 high power (×60) confocal images per patient, typically including 100 to 200 endothelial nuclei in total per patient. The channel depicting ERG was used to define each endothelial nucleus as a separate region of interest, and the mean signal intensity in the channel depicting csNICD1 was measured for each region of interest. CD45 positive cells were counted automatically from merged images (n=8 per group) obtained using a Zeiss Axioscan Z1 slide scanner with filter sets 38 HE and 49 and analyzed using the Measure>Analyze particle function in ImageJ. Blinded automatic quantification of VCAM1 signal was performed using 5 ×20 fields from each dinitrofluorobenzene-treated ear (n=8 mice per group). The region from the middle of the cartilage of the pinna to the inner epidermal border was selected manually using the region of interest tool. Autofluorescent noise was reduced by subtracting 25 arbitrary units from the fluorescent signal.
Integrated density values (representing the product of number of pixels measured and the mean gray value per pixel) were normalized using the ratio between measured area in that section to the mean area of all sections measured. Because edema is mainly confined to one side of the pinna, VCAM1 signal was measured on the opposite side, thus allowing similarly sized region of interests between the different mice.
Knockdown Experiments
Silencer select predesigned siRNAs for JAG1, DLL4, NOTCH1, negative controls, and transfection reagents were obtained from Thermo Fisher Scientific. Initial transfections ( Figure 1 ) were performed on HUVECs in suspension incubated with a precomplexed mixture of siPORT amine transfection agent and 40 nmol/L siRNA oligonucleotides in Opti-MEM and plated at a density of 7.2×10 4 cells/cm 2 . The protocol was later optimized, and HUVECs were instead plated 3×10 4 cells/cm 2 and transfected the next day using lipofectamine RNAimax and 27 nmol/L siRNA. The medium was replaced by regular growth medium after 6 hours. Unless otherwise stated, IL-1β was added at 5 ng/mL 48 hours post-transfection, and the cultures were incubated for the indicated time.
In Vitro Stimulation and Blocking of Notch Signaling
For immobilization of JAG1 and DLL4, 6-well culture plates (Corning, Inc) were first incubated with goat polyclonal antihuman IgG (I3382, 6.48 µg/mL; R&D Systems) or rabbit polyclonal anti-His (A00174, 6.48 µg/mL; GenScript) as described previously 20 and then with recombinant JAG1-Fc (1277-JG, 2.47 µg/mL; R&D Systems) or DLL4-His (1506-D4, 1 µg/mL; R&D Systems), respectively. rhIgG 1 -Fc or BSA were used as controls. HUVECs were seeded at 2.5×10 4 cells/cm 2 and harvested after 24 to 48 hours. All antibodies used for in vitro blocking of JAG1, Dll4, and NOTCH1 in HUVECs and respective working concentrations are specified in the Major Resource Tables in the online-only Data Supplement. Species-, isotype-, and concentration-matched monoclonal antibodies against the E-tag peptide (clone 73009; R&D Systems), KLH (clone 11711; R&D Systems), Aspergillus niger glucose oxidase (clone DAK-GO1; DakoCytomation), or human IgG1 (Genentech) were used as negative controls. Antibodies were added to the culture 1 hour before the addition of IL-1β.
Cellular Fractionation and Transcription
Factor DNA-Binding ELISA HUVECs were fractionated into nuclear extract and cytoplasmic extracts by the Nuclear Extract Kit from Active Motif. When used for Western blotting, a 6× SDS buffer was added to the extracts to match the Western blotting conditions described below. The DNA-binding potential of nuclear RELA (v-rel avian reticuloendotheliosis viral oncogene homolog A), p50, cFOS, and phosphorylated cJUN (Ser73) was measured by the TransAM Transcription Factor ELISA kits from Active Motif.
Protein Extraction and Western Blot
Cells were washed twice in PBS before lysis in an SDS buffer (2% SDS, 50 mmol/L Tris-HCl, 10% glycerol, 0.08% bromophenol blue, 100 mmol/L β-mercaptoethanol, Complete Protease and PhosStop Phosphatase inhibitor cocktails from Roche) to prepare whole cell extracts. Protein concentrations were determined by the RC DC Protein Assay from Bio-Rad.
Protein extraction from samples used for microarray analysis was done from the organic phase of TRI Reagent samples as described previously. 21 The dialysate was centrifuged, and the clear supernatant was concentrated 10-fold in Vivaspin sample concentrators (Sartorius AG). Protein concentration was determined on the Nanodrop ND-1000 Spectrophotometer (Thermo Scientific). Western blotting was performed on equal protein amounts (10-20 µg) by a Bio-Rad workflow (Mini-PROTEAN TGX Precast Gel, Trans-Blot Turbo Transfer System with Nitrocellulose Transfer Packs, and ChemiDoc MP System) with the exception that the SuperSignal West Dura substrate from Thermo Fisher Scientific was used for ECL detection. Five percent Blotting-Grade Blocker (Bio-Rad) in TBS with 1% Tween 20 was applied for membrane blocking except for phosphoprotein detection where 5% BSA was used. Membranes were incubated with primary antibodies at 4°C overnight, followed by HRP-linked secondary antibody, 1 hour at room temperature. HRP signal was detected by chemiluminescence (substrate 32106 or 34076; Pierce, Thermo Scientific) and analyzed on a Kodak Image Station 4000R. All primary antibodies used for Western blot are listed in the Major Resource Tables in the online-only Data Supplement.
Cellular ELISA
Total cellular expression of VCAM1 was quantified by CELISA on fixed, adherent HUVECs as described previously.
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Flow Cytometry
Single-cell suspensions obtained by gentle EDTA treatment (≈10 minutes; 5 µmol/L in PBS) of HUVECs were incubated on ice (30 minutes) with primary antibodies specified in the Major Resource Tables in the online-only Data Supplement followed by R-phycoerythrin-labeled goat anti-mouse IgG 1 conjugate (1072-09, 2 µg/mL; Southern Biotech) for 20 minutes. The final suspension was made in medium containing TO-PRO-3 iodide (1 µmol/L; Life Technologies). An irrelevant isotypeand concentration-matched primary antibody served as control. The samples were analyzed on a fluorescence-activated cell sorter (FACScalibur; Becton Dickinson). For quantification of leukocytes from mouse ears, cell suspensions were obtained as described below (collection and sorting of mouse endothelial cells), and CD45+ cells were incubated on ice (30 minutes) with antibodies as specified in the Major Resource Tables in the online-only Data Supplement. The samples were analyzed on a fluorescence-activated cell sorter (FACSAria II; Becton Dickinson).
Gene Expression Profiling and Gene Ontology Analysis
Total RNA was isolated using the RNeasy Mini or Micro Kits (Qiagen) as recommended by the manufacturer. Human gene expression profiles were obtained by Illumina HumanHT-12 v4 Expression BeadChips and mouse expression profiles by Affymetrix Mouse Gene ST 2.1 Arrays. Data have been deposited as a super series in National Center for Biotechnology Information GEO (Gene Expression Omnibus) 23 and are accessible through GEO accession number GSE85987. Raw data were imported into R (version 3.3.0)/Bioconductor/Beadarray 24 (Illumina) or Oligo 25 (Affymetrix) and quantile (human) or RMA (robust multi-array average; mouse) normalized. Differentially expressed genes were identified by using the moderated t approach in R/Bioconductor/Limma. 26 The Benjamini-Hochberg method was used to control the false discovery rates. Gene Ontology analysis 27 was performed using the GO Consortium database (version released, 20160822) and the Panther overrepresentation test (version released, 20160715).
Real-Time Quantitative Polymerase Chain Reaction
For real-time quantitative polymerase chain reaction (qPCR), HUVECs were lysed directly in the culture dish with TRI Reagent. Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. RNA was reverse transcribed using Oligo(dT) and Superscript III reverse transcriptase (Life Technologies). Gene transcripts were quantified using the Mx3000P system (Agilent Figure IE in the online-only Data Supplement. E-F, RT-qPCR for VCAM1, HEY1 (Hairy/enhancer-of-split related with YRPW motif protein 1), CX3CL1, and DARC using RNA isolated from HUVECs (E) exposed to IL-1β (5 ng/mL, 24 h) in the presence of a blocking antibody to JAG1 or isotype control, (F) plated on immobilized Jagged1 Fc (24 h). *P<0.05, **P<0.01, ***P<0.001. Mann-Whitney U (D and E) or Kruskall-Wallis followed by Dunn multiple comparison test (F). See also Figure I in the online-only Data Supplement. CXCL indicates chemokine (C-X-C motif) ligand; and ICAM1, intercellular adhesion molecule 1.
Technologies), normalized against hypoxanthine-guanine phosphoribosyl transferase, and fold changes calculated according to the comparative C T method. 28 Sequences of qPCR primers used in this study are given in the Major Resource Tables in the online-only Data Supplement.
Chromatin Immunoprecipitation Sequencing
Chromatin immunoprecipitation (ChIP) combined with deep sequencing (ChIP-seq) was performed on pools of HUVECs from 13 donors grown on 15 cm 2 culture dishes. Cells used for NOTCH1 and RBPJ ChIP-seq were cultured 48 hours beyond reaching confluence to induce quiescence 29 before crosslinking and harvest. Cells used for RELA and H3K27ac (histone H3 acetylated at lysine 27) ChIP-seq were transfected with NOTCH1 or Scr siRNA 60 hours before stimulation with IL-1β for 1 hour. Knockdown efficiency was assessed by Western blotting in parallel experiments. ChIP for RELA, NOTCH1, and RBPJ was performed on HUVECs as described previously 16 with the exception that a 2-step crosslinking procedure (45 minutes in 2 mmol/L di-succinimidyl glutarate followed by 10 minutes in 1% formaldehyde and quenching in 125 mmol/L glycine) 30 and longer sonication (24 cycles of 30 seconds on/off at high intensity at the Bioruptor Twin) were applied. For H3K27ac ChIP-seq, only 10 minutes of formaldehyde crosslinking was applied. Cells were lysed in 1.6 mL lysis buffer (0.1% SDS, 1% Triton X-100, 0.15 mol/L NaCl, 1 mmol/L EDTA, and 20 mmol/L Tris pH 8), removed with a cell scraper, and kept at 4°C (NOTCH1 and RBPJ) or −80°C (RELA and H3K27ac) before sonication. disuccinimidyl glutarate/formaldehyde and formaldehyde samples were sonicated for 40 or 16 cycles, respectively, as described for ChIP-qPCR. To remove cell debris, samples were centrifuged at 10 000 g for 1 minute. Immunoprecipitation was performed in 15-mL tubes containing 1.5×10 7 cells in a final volume of 6-mL lysis buffer with 1 mg/mL BSA. Chromatin was incubated with antibodies (see the Major Resource Tables in the online-only Data Supplement) for 3 hours at 4°C with upside-down rotation. Protein A sepharose beads (150 µL per ChIP-seq washed thrice in lysis buffer and resuspended in a final of 750 µL lysis buffer with 750 µg BSA) were added and samples were incubated overnight at 4°C with upside-down rotation. Beads were washed in 12 mL wash buffers as follows: 2× wash buffer 1 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.15 mol/L NaCl, 1 mmol/L EDTA, 20 mmol/L HEPES), 1× wash buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 mol/L NaCl, 1 mmol/L EDTA, 20 mmol/L HEPES), 1× wash buffer 3 (0.25 mol/L LiCl, 0.5% NaDOC, 0.5% NP-40, 1 mmol/L EDTA, 20 mmol/L HEPES), and 2× wash buffer 4 (1 mmol/L EDTA, 20 mmol/L HEPES), before treatment with RNase A (100 microgram/ mL) in water for 20 minutes at 37°C and elution in 2×200 µL buffer (0.1 mol/L NaHCO3, 1% SDS) for 2×15 minutes at room temperature with upside-down rotation. Samples were then treated with 60 µg proteinase K for 1 hour at 55°C and subjected to decrosslinking in 300 mmol/L NaCl by overnight incubation at 65°C. DNA was purified by standard PCI (phenol:chloroform:isoamyl alcohol) extraction and ethanol precipitation and resuspended in 60 µL water. For input samples, 0.7% sonicated material was processed in parallel to the ChIP-seq samples from the RNase-treatment step. Chromatin shearing was assessed by agarose gel electrophoresis, and ChIP-seq quality was tested by ChIPqPCR. DNA concentration was determined by the Quant-iT PicoGreen dsDNA assay kit from Life Technologies. Samples of 10 ng were used for library preparation by the Illumina sample preparation kit before sequencing on Illumina Hiseq4000 (RBPJ, NOTCH1) or Illumina Nextseq500 (RELA, H3K27ac) instruments.
ChIP-Seq Analysis
Samples were sequenced on an Illumina Hiseq4000 (RBPJ, NOTCH1) or Illumina Nextseq500 (RELA, H3K27ac) machine as described above. Fastq files were mapped to hg19 reference genome from Illumina iGenomes database, using bow tie. 31 Some samples were sequenced as paired-end 151 bp reads (RBPJ, NOTCH1) and some as single-end 75 bp reads (RELA, H3K27ac). Paired-end sequences overlapped their respective mates in genomic position. Thus, only 1 mate was used for the paired-end samples. Duplicate reads were filtered out using the rmdup function from SAMtools suite. 32 Data were converted to bigWig format and viewed in the Integrative Genomics viewer to generate screenshots. 33 Peak calling was performed using callpeak function from macs2. 34 Peaks overlap data were generated by using multiinter function of the BEDTools suite. 35 Base-pair overlap was calculated by a custom Perl script, which counted the number of bases in each intersect. Average profiles were generated by using ngs.plot.r 36 and replotted in R 37 with ggplot. 38 All NOTCH1 peaks were used for average profile enrichment around NOTCH1 peaks. For RELA average profiles, all peaks were combined, and common regions were merged using merge function from BEDTools suite. Endothelial superenhancer regions were obtained from Brown et al 16 and lifted to hg19. TNF-induced endothelial superenhancers overlapping with NOTCH1 peaks were identified, and basepair overlaps with H3K27ac peaks in the IL-1β-stimulated samples with or without NOTCH1 knockdown were determined as above.
Mice
Mouse strains used are described in the Major Resource Tables in the online-only Data Supplement. Genotyping was performed as described previously. 39 To trigger Cre-mediated gene inactivation (Rbpj) or homozygous constitutive activation (NICD) in postnatal mice, intraperitoneal injections of 1 mg tamoxifen (Sigma T5648) dissolved in a mixture of ethanol, polyethoxylated castor oil (Kolliphor EL; BASF Corp), and PBS 1:1:8 were given daily for 5 consecutive days, starting 6 days before sensitization with dinitrofluorobenzene unless indicated otherwise. The specificity and efficiency of Cre activity were verified by reporter lines. Pharmacological inhibition of Notch signaling via DAPT in vivo was performed in 11-weekold female C57BL6/JBomTac mice. Subsequent experiments were performed in transgenic animals of both sexes, 5 to 14 weeks old. Animals were matched according to sex and age, and the effects of Notch modulation were similar in females and males. Transgenic animals of both sexes, 9 to 11 weeks old, were used for isolation of endothelial cells for transcriptome analysis. A total of 161 mice were used in this study. Power analysis was used to estimate the number of animals required per treatment group. Randomization of treatment groups was not performed. Operators were blinded to the genotype in animal experiments. All experiments involving animals were performed according to institutional guidelines and laws, following protocols approved by local animal ethics committees.
Murine Contact Hypersensitivity Model
Dinitrofluorobenzene-induced contact hypersensitivity ( Figure IIIA in the online-only Data Supplement) is a delayed-type hypersensitivity model for human allergic contact dermatitis. Mice were sensitized to dinitrofluorobenzene by painting the shaved abdomen with 25 µL of a 0.5% solution in acetone/olive oil (4:1), in addition to 5 µL to each paw, on days 0 and 1. For systemic inhibition of Notch signaling, 100 mg/kg DAPT dissolved in 10% ethanol and 90% corn oil was administered subcutaneously caudally on the back (injection volume, 10 µL/g body weight) 3 hours before ear challenge on day 5. Control mice were injected with vehicle only. On day 5, the elicitation phase was induced by painting the right ear with 20 µL of 0.5% dinitrofluorobenzene solution. The thickness of the ears was measured using a micrometer. Swelling was calculated by subtracting the baseline thickness from the thickness measured at various time points. Anesthesia was induced by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (100 mg/kg) or isoflurane inhalation. No animals were excluded from analysis.
Isolation of RNA From Mouse Ear Endothelial Cells
Mouse ears were collected and washed in sterile PBS, hair was removed, and the ears were minced thoroughly using 2 scalpel blades. Minced tissue was transferred to 1% collagenase I dissolved in prewarmed 5% BSA-PBS and incubated 2 hours at 37°C on a horizontal shaker. DNAse I was added in the last 30 minutes of incubation. Finally, to obtain a single-cell suspension, samples were passed through a 50-μm cell strainer and washed thrice in fluorescence-activated cell sorter buffer (2% FCS, 2 mmol/L EDTA in PBS). Endothelial cells were then sorted in a FACSAria II, directly into RLT buffer, as a CD45-/Ter119-/CD31+ subpopulation with antibodies specified in the Major Resource Tables in the online-only Data Supplement. The samples were kept at −80°C until RNA was extracted using the Qiagen RNEasy Plus Micro kit. The RNA amount and integrity were assessed using RNA 6000 Pico Kit (Agilent Technologies) in a 2100 Bioanalyzer (Agilent Technologies); only RNA samples with RIN values >7 were used for downstream microarray analysis. Samples were transported on dry ice to a commercial provider where they were amplified using the Affymetrix WT Pico Amplification kit and hybridized on the Affymetrix Gene Chip Mouse Gene 2.1 ST Array.
Statistical Analysis
Statistical analyses were performed using Mann-Whitney U test, Wilcoxon signed-rank test, or Kruskall-Wallis test followed by Dunn multiple comparison test, all in GraphPad Prism (version 6.0h). Because most sample sizes were too small to ensure normal distribution of data, we chose to use nonparametric statistical tests. Microarray data were analyzed using R/Bioconductor/Limma 26 by the moderated t approach and Benjamini-Hochberg adjustment for multiple comparisons.
Results
Proinflammatory Cytokines Selectively Drive JAG1 Expression in Endothelial Cells
Endothelial JAG1 is upregulated by TNF-α via activation of NF-κB and AP-1 (activator protein-1). 40 We, therefore, assessed the proinflammatory responsiveness of all endothelial Notch ligands in HUVECs, observing that the response was restricted to JAG1 and that IL-1β, compared with TNF-α, induced an even stronger upregulation of JAG1 mRNA ( Figure 1A ). In addition, IFN-γ also gave a moderate response ( Figure 1A) . At the protein level, cell surface expression of JAG1 was upregulated by IL-1β in a dose-and time-dependent manner, peaking at 5 ng/mL and 12 hours, respectively ( Figure IA and IB in the online-only Data Supplement).
JAG1 Promotes Inflammatory Gene Expression in Endothelial Cells
To address whether JAG1 plays a role in inflammatory activation of endothelial cells, we next performed genome-wide transcriptome analysis of IL-1β-stimulated HUVECs treated with siRNA targeting JAG1 or scrambled siRNA, identifying 135 differentially expressed genes in IL-1β-stimulated cells (fold change, >1.5; Benjamini-Hochberg adjusted P<0.05; Figure  IC in the online-only Data Supplement, genes listed in Table  I in the online-only Data Supplement). Gene ontology analysis revealed that genes supported by JAG1 in IL-1β-stimulated cells were enriched for biological terms associated with leukocyte recruitment (chemokine-mediated signaling pathway, positive regulation of leukocyte chemotaxis), response to proinflammatory stimuli (IFN-γ-mediated signaling pathway, cellular response to IL-1, cellular response to TNF, response to lipopolysaccharide, and response to virus), and inflammatory activation (immune effector process, inflammatory response; Figure 1B ; Table II in the online-only Data Supplement). In contrast, genes repressed by JAG1 in IL-1β-stimulated cells were enriched for biological terms associated with hypoxia and apoptosis ( Figure 1B ; Table III in the online-only Data Supplement). Interestingly, although knockdown of JAG1 markedly inhibited the expression of selectins (SELE and SELP) and adhesion molecules (VCAM1 and ICAM1) in IL-1β-stimulated HUVECs, the effect on chemokines and associated molecules was much more variable, with some being markedly reduced (DARC [Duffy antigen receptor of chemokines], CCL8, and CX3CL1), whereas others remained unaffected (CXCL8 and CCL2; Figure 1C ).
Results were validated by means of real-time qPCR ( Figure ID in the online-only Data Supplement). The modulation of VCAM1, CX3CL1, and DARC after JAG1 knockdown was confirmed at the protein level by flow cytometry ( Figure 1D ; Figure IE in the online-only Data Supplement). To corroborate the specificity of the knockdown, we also inhibited the function of JAG1 in IL-1β-stimulated cells by means of a neutralizing antibody, observing modulation of target transcripts similar to that observed in response to siRNA treatment ( Figure 1E ). Furthermore, we inverted the experiment by seeding cells on immobilized recombinant JAG1 in the absence of proinflammatory cytokines, observing enhanced expression of target genes ( Figure 1F ). It should, however, be noted that JAG1 siRNA did not inhibit the expression of inflammatory transcripts in the absence of IL-1β-stimulation (Table IV in the online-only Data Supplement).
Altogether, these results show that inhibition of endothelial JAG1 attenuates the upregulation of a subset of inflammatory mediators with established roles in leukocyte recruitment.
JAG1 Maintains Expression of NOTCH1-Supported Genes in Activated Endothelial Cells
Considering the dynamic and competitive balance between JAG1 and DLL4 during angiogenic sprouting 20 and the suggested role of JAG1 in priming endothelial cells for angiogenesis after inflammatory activation, 41 we next asked whether JAG1 reinforced or inhibited the expression of NOTCH1-supported genes in IL-1β-stimulated HUVECs. Comparing transcriptome data from confluent HUVECs treated with siRNA targeting NOTCH1 to 2 published data sets investigating the effect of inhibiting overexpressing NOTCH1 in cultured human endothelial cells, 10, 42 we compiled lists of genes supported or repressed by NOTCH1 in at least 2 of the 3 data sets (Figure 2A) . Gene set enrichment analysis showed that JAG1 knockdown mediated negative enrichment of NOTCH1-supported genes (Figure 2A and 2B) and positive enrichment of NOTCH1-repressed genes (Figure 2A and 2C ) in IL-1β-stimulated HUVECs.
JAG1 Inhibition Is Mirrored by Targeting DLL4 or NOTCH1
HUVECs seeded on immobilized recombinant DLL4 substantially increased their expression of VCAM1 and DARC ( Figure 2D ) and inhibition of DLL4 by a neutralizing antibody reduced the IL-1β-induced transcription of VCAM1, DARC, and CX3CL1 in a similar manner to JAG1 inhibition ( Figure 2E ). Moreover, administration of a neutralizing antibody against NOTCH1 reduced the IL-1β-induced expression of VCAM1, DARC, and CX3CL1 ( Figure 2F ). Finally, siRNA-mediated knockdown of NOTCH1, JAG1, or DLL4 inhibited VCAM1 protein expression as detected by a cellbased ELISA assay ( Figure 2G) . Notably, and despite the marked increase in JAG1 expression during inflammatory activation, JAG1, DLL4, and NOTCH1 knockdown all attenuated VCAM1 induction with similar kinetics. It should also be noted that the effect of IL-1β on NOTCH1-supported genes was diverse ( Figure II in the online-only Data Supplement), with some genes (eg, FABP4 and FOXC1) being induced and G   CXCR4  PGF  TMEM158  FAM89A  HLX  PHLDA1  CCND1  C16ORF74  SLC7A5  TRIP13  CKS1B  NES  FEN1  MAD2L1  SNHG9  CEP55  SPOCD1  ANGPT2  DDX18  MELK  FERMT3  DTYMK  PLAUR  TUBB4B  CXCL8  RPL39L  COL13A1  TUBA1A  CD276  LHX6  LYVE1  CTHRC1  ABHD17C   LYPD1  ACOT7  TXNIP  HES4  HES1  HEY2  TAGLN  IFI44L  DKK3  BMP4  ALPL  RND3  MX1  SLC30A3  CCL2  NREP  SAT1  CAP2  ADGRG6  ALDH1A1  N4BP2L2  SPINT2  CLEC3B  PTGS2  MDK  IFITM1  FILIP1L  METTL25  KLHL13  ACOX2  FGF2  DSE  CEACAM1  GUCY1A3  FABP4  PLAC9  CDH11  COBLL1  HTRA1  CASP1  ART4  SELP  EFNB2  CFH  PSMB10  FBXO32  PARP12  GAS6  MAOA  FOXC1  GBP1  ADGRA2  STAT1  ABLIM1  CPE  MATN2  STAT4  LAP3  COL8A1  IL18BP  GJA4  SLC15A3  RARRES3  LEPR  UBE2L6  IL33  SULF1  LGALS9  IL18R1  SLC40A1  RBP1  VCAM1  HAPLN3  TNFSF10   siJAG1 Taken together, these data show that JAG1, DLL4, and NOTCH1 all support the upregulation of a similar subset of inflammatory mediators in cultured human endothelial cells and confirm previous observations that the cytokine-induced upregulation of JAG1 serves to maintain NOTCH1 signaling under inflammatory conditions.
NOTCH1 Is Activated in Endothelial Cells of Inflamed Human Appendix
Considering that NOTCH1 signaling supported the upregulation of leukocyte-recruiting factors in vitro, we next asked whether active NOTCH1 could be observed in endothelial cells of inflamed human tissues. When immunostaining biopsies with an antibody that recognizes the intracellular domain of human NOTCH1 only when released by cleavage before Val1754 43 (csNICD1), we observed strong csNICD1 signal in endothelial cells of a subset of vessels in inflamed appendix ( Figure 3A) . Endothelial identity was confirmed by costaining with the endothelial-specific transcription factor ERG. We next quantified the nuclear csNICD1 signal in lamina propria endothelial cells (ERG positive) and observed significantly higher levels of csNICD1 in biopsies with moderate-to-severe inflammation (scores ++ or +++) than in biopsies with no or little inflammation (scores 0 or +; Figure 3B ).
Because leukocyte recruitment takes place at the level of postcapillary venules, we next mapped the endothelial csNICD1 signal in different branches of the vascular tree. To this end, we used morphological criteria and a panel of molecular markers (detailed in Table V in the online-only Data Supplement) to identify arterioles, venules, capillaries, and lymphatic vessels. In noninflamed control specimens ( Figure 3C through 3E) , we observed a strong nuclear signal for csNICD1 in endothelial cells of arteriolar and lymphatic vessels (VE-cadherin positive, VWF [von Willebrand factor] negative, sparse cytoplasm, absence of aSMA-positive perivascular cells), whereas the majority of mucosal and submucosal venular endothelial cells (positive for the postcapillary venule-specific marker DARC, 44 not shown) were negative or only weakly positive for csNICD1 under matching conditions for staining and exposure ( Figure 3D and 3E, labeled a, L, and v, respectively). By contrast, postcapillary venules of inflamed specimens ( Figure 3F through 3H, labeled v) altogether showed an induction of nuclear endothelial signal for csNICD1 at the mucosal-submucosal border. Together, these findings suggest that endothelial NOTCH1 signaling in the gastrointestinal tract is subject to spatial and temporal regulation in the context of inflammation.
Notch Signaling Modulates the Contact Hypersensitivity Response
To evaluate the functional importance of our observations, we used the dinitrofluorobenzene-induced contact hypersensitivity model ( Figure IIIA in the online-only Data Supplement). We observed that subcutaneous injection of the γ-secretase inhibitor DAPT 3 hours before dinitrofluorobenzene challenge (blocking Notch signaling in all cell types) inhibited ear swelling at 12 hours and that the effect of DAPT became even more pronounced 24 hours after challenge ( Figure 4A) .
To understand the relative contribution of endothelial Notch signaling to inflammation, we asked to what extent endothelial cell-targeted loss and gain of Notch function would affect the contact hypersensitivity response. We found that mice with deletion of Rbpj in endothelial cells (Rbpj iΔEC ) showed a significant reduction in ear swelling 24 hours after challenge ( Figure 4B ). Complementary, mice that expressed constitutively active endothelial Notch1 (NICD iEC-OE ) responded by a significantly stronger ear swelling compared with controls ( Figure 4C) . Collectively, these results show that not only global but also endothelial Notch signaling modulates the contact hypersensitivity response.
Endothelial Notch Signaling Supports Leukocyte Recruitment
We next asked whether Notch signaling also affected leukocyte recruitment to the inflamed lesion. By immunostaining and quantifying CD45+ cells in dinitrofluorobenzene-treated ears 24 hours after challenge, we observed increased numbers of total leukocytes ( Figure 4D ; Figure IIIB in the online-only Data Supplement), CD3+ dermal T cells ( Figure 4E ; Figure  IIIC in the online-only Data Supplement), and neutrophils (Ly6G+ cells; Figure 4F ) in NICD iEC-OE mice when compared with control mice. NICD iEC-OE mice also showed increased recruitment of monocytes (CD11b+Ly6C+ cells, fraction of total CD45+ population; Figure 4G ). These findings demonstrate that an amplification of endothelial Notch1 signaling promotes leukocyte recruitment to the inflamed dermis in murine contact hypersensitivity.
Notch Regulates Common Inflammatory Genes in Human and Mouse Endothelial Cells
To identify genes that were consistently altered by Notch signaling in activated endothelial cells, we next compared transcriptome data from mouse endothelial cells isolated from dinitrofluorobenzene-treated ears of NICD iEC-OE mutants and HUVECs treated with siRNA targeting JAG1 or NOTCH1 and stimulated with IL-1β. This approach identified 11 genes that were differentially regulated by all conditions (Figure 4H ), including VCAM1 and CX3CL1, as well as Notch target genes with established roles in vascular differentiation (HEY1 [Hairy/enhancer-of-split related with YRPW motif protein 1] and EFNB2).
Confirming our transcriptional data, immunostaining of sections from mouse ears with an antibody recognizing VCAM1 showed increased VCAM1 signal in NICD iEC-OE mice compared with controls ( Figure 4I ; Figure IIID in the online-only Data Supplement). VCAM1 is upregulated by dinitrofluorobenzene exposure 45 and allows firm adhesion of T cells, monocytes, and eosinophils that express the integrin heterodimer α4β1/VLA-4 (very late antigen-4). A neutralizing antibody to VLA-4 is furthermore reported to partially block dinitrofluorobenzene-induced contact dermatitis, 46 suggesting that the observed increase in VCAM1 is likely to be physiologically significant.
In conclusion, the NOTCH1 effect observed in cultured human endothelial cells translates at least, in part, to the in vivo situation and contributes to explain the phenotype of NICD iEC-OE mice in dinitrofluorobenzene-induced contact hypersensitivity.
Inhibition of NOTCH1 Does Not Affect NF-κB and AP-1 Signal Transduction in Endothelial Cells
To dissect the mechanism by which NOTCH1 supported endothelial inflammatory activation, we next assessed whether NOTCH1 inhibition altered IL-1β-induced signaling in endothelial cells. The IL-1β-induced signaling cascade involves IKK (inhibitor of nuclear factor kappa-B kinase)-and MAPK-dependent activation of the master inflammatory transcription factors NF-κB (RELA and p50) and AP-1 (cJUN and cFOS), 47 and NOTCH1 has been reported to directly 3,4,11 or indirectly 48 promote the activity of the IKK signalosome complex. We found, however, no evidence for such crosstalk in IL-1β-stimulated HUVECs because NOTCH1 knockdown by siRNA altered neither the phosphorylation, degradation, or resynthesis of IκBα ( Figure  IVA C and F) , respectively, and show the channel detecting csNICD1 signal in grayscale. Venules (v, red outlines), arterioles (a, blue outlines), and lymphatic vessels (L, yellow arrows) are indicated. E and H, Three-color (csNICD1, VWF, and hoechst) higher magnification images of the areas identified by white boxes in (C and F), respectively. Scale bars represent 50 μm. Note that crypt epithelial cells (CECs) also show a positive signal for nuclear csNICD1. Exposures were identical for matched images (D and G) and (E and H), respectively. Image contrast was stretched to enhance visualization, applying identical settings for inflamed and noninflamed tissues. WBC indicates white blood cell.
Genomic Sites Occupied by the NOTCH1 Transcription Complex Are Also Binding Sites for RELA
Considering that NOTCH1 inhibition markedly reduced the upregulation of selected inflammatory genes but had little impact on inflammatory signaling cascades, we asked whether the NOTCH1 transcription complex might in itself promote favorable conditions for transcriptional activation of these genes. We, therefore, profiled the genomewide binding of canonical components of the NOTCH1 transcription complex (NOTCH1-RBPJ [recombination signal-binding protein for immunoglobulin kappa J region]) and the NF-κB subunit RELA, as well as the deposition of H3K27ac-a measure of enhancer activity 49 that can be promoted by the genomic impact of both NOTCH1 17, 18 and NF-κB. 16, 50 ChIP combined with deep sequencing (ChIP-seq) was first performed in confluent, resting HUVECs to generate genome-wide binding profiles of NOTCH1 and RBPJ, identifying a total of 4328 and 11 345 peaks ( Figure 
NOTCH1 Transcription Complex Promotes Activation of Inflammatory Enhancers
We next manually explored the binding of the NOTCH1 transcription complex in the proximity to JAG1/NOTCH1-supported genes. RBPJ peaks were identified in or close to transcriptional start sites of canonical NOTCH1 target genes, including HES1 ( Figure 5B ) and IL33 ( Figure VIA in the online-only Data Supplement), as well as some of the JAG1/ NOTCH1-supported genes involved in leukocyte recruitment, including ICAM1 ( Figure 5C ) and SELP ( Figure VIB in the online-only Data Supplement). In contrast, RBPJ did not bind in or near transcriptional start sites of the JAG1/NOTCH1-supported genes VCAM1 (Figure 5D) , CCL7, or CCL8 ( Figure 5E ) but instead occupied nearby (±100 kB) regions recently described as inflammatory superenhancers, based on strong, TNF-α-induced BRD4 enrichment. 16 Interestingly, the RBPJ-peak close to the ICAM1 transcriptional start site was also associated with one of these inflammatory enhancers ( Figure 5C ). In all examined regions, NOTCH1-binding patterns mirrored those of RBPJ, but the signal was generally weaker, resulting in fewer called peaks.
Notably, the identified NOTCH1/RBPJ peaks in the VCAM1-assigned enhancer overlapped with binding of RELA in IL-1β-stimulated cells ( Figure 6A ), and NOTCH1 knockdown almost completely abrogated the IL-1β-induced activity around this site as judged by the deposition of H3K27ac ( Figure 6A ). The same pattern was observed in the inflammatory enhancer region associated with the CCL2-CCL7-CCL11-CCL8 locus ( Figure 6B ).
Our findings prompted us to ask whether the NOTCH1 transcription complex exerted a net effect on the activation of inflammatory enhancers. Taking advantage of the previously defined set of inflammatory enhancers, 16 we detected RELA binding within all of these regions and found that a large subset was also bound by NOTCH1 (41%) and RBPJ (77%; Figure 6C ). Importantly, when focusing on those regions containing NOTCH1 peaks (all of which also contained RBPJ peaks; Figure 6C ), we discovered that the increased mean peak intensity of H3K27ac elicited by IL-1β stimulation was strongly attenuated on NOTCH1 knockdown ( Figure 6D) . Furthermore, the extent of H3K27ac peak overlap within the same regions was reduced by 31% after NOTCH1 knockdown ( Figure 6E ). Taken together, these results suggest that the transcription complex of NOTCH1-RBPJ facilitates the activation of a subset of strong NF-κB-directed enhancers central to the endothelial inflammatory response that mediates leukocyte recruitment.
Discussion
Endothelial cell activation is a crucial component of the inflammatory response. Here, we provide the first evidence that NOTCH1 supports the inflammatory endothelial phenotype that mediates leukocyte recruitment by facilitating activation of inflammation-driven enhancers. Our conclusions build on the following observations: first, we demonstrate that JAG1/NOTCH1 globally modulates the transcriptional response to inflammatory cytokines; second, we observe that NOTCH1 signaling contributes to the inflammatory response in vivo; and third, we show that the transcription complex acting downstream of NOTCH1 signaling occupies inflammatory loci targeted by NF-κB and facilitates activation of inflammatory enhancers central to the endothelial inflammatory program. 16 Previous data demonstrate that NOTCH1 signaling may promote inflammatory activation by crosstalk with inflammatory signaling cascades, perhaps best illustrated in the NF-κB pathway. For example, NOTCH1 can induce NF-κB activation and cellular survival in cancer cells by direct interactions between NICD1 and the IKK signalosome that facilitates cytoplasmic IκBα degradation.
3,4 NICD1 has also been reported to directly interact with NF-κB subunits, affecting their nuclear import and retention.
11,51,52 It nevertheless appears, based on our analyses, that these mechanisms are of less importance in human endothelial cells. Our combined findings demonstrate that acute NF-κB signaling to RELA-p50 remains unaffected by NOTCH1 knockdown and that the recruitment of RELA to chromatin, as assessed by genome-wide ChIP-sequencing, is not reduced. This agrees with observations made by ourselves and others 10 that some NF-κB targets, like CXCL8 and CXCL1, remain unaffected or are even induced by NOTCH1 inhibition. Moreover, the current model cannot explain how NOTCH1 supports the expression of P-selectin-another leukocyterecruiting molecule that is not driven by NF-κB activation.
By contrast, our data indicate that NOTCH1 supports inflammatory activation of endothelial cells at the chromatin level by globally promoting inflammatory enhancer activity and that its transcription complex also binds directly to the transcriptional start sites of some inflammatory genes (SELP and ICAM1). Indeed, we discovered that most sites occupied by the NOTCH1 transcription complex in endothelial cells are inflammatory in the sense that they are bound by RELA after IL-1β stimulation. Although our data are the first to reveal an effect of NOTCH1 on inflammatory enhancers, NOTCH1 has been reported to promote recruitment of IKKα to IKKα-stimulated promoters in cervical cancer cells, 4 indicating that it may also support the ability of IKKα to mediate derepression of NF-κB target genes. 53 Altogether, our data take the understanding of NOTCH1 function in inflammation to a new level by demonstrating a profound involvement in inflammatory enhancer activation.
Our data support a model in which the NOTCH1 transcription complex assists the NF-κB-driven machinery in orchestrating activation of inflammatory enhancers central to controlling the endothelial inflammatory phenotype. Notably, this mode of regulation was apparent at the VCAM1 locus ( Figures 5D and  6A ), which stood out as one of the most robustly NOTCH1-supported genes in our transcriptional analyses. It should be noted that although the depicted enhancer was recently assigned to VCAM1, 16 its functional impact on VCAM1 expression remains to be confirmed; for example, by genomic deletion or epigenetic inactivation of the enhancer. Of note, the enhancer is directly associated with a long intergenic nonprotein-coding RNA (LINCO1349), and NOTCH1 has previously been shown to coregulate coding transcripts without an obvious NOTCH1-binding site near the transcriptional start site and noncoding transcripts associated with distal NOTCH1-bound enhancers.
Another interesting enhancer region is associated with the CCL2-CCL7-CCL11-CCL8 locus ( Figures 5E and 6B) . We observed that although basal CCL2 expression was consistently supported by NOTCH1 in unstimulated HUVECs, neither JAG1 nor NOTCH1 inhibition had any effect on its upregulation after IL-1β stimulation ( Figure 1C , Table I in the online-only Data Supplement, and submitted microarray data GSE85987). In contrast, JAG1 and NOTCH1 supported the IL-1β-stimulated transcriptional upregulation of the adjacent genes CCL7 and CCL8 ( Figure 1C , Table I in the online-only Data Supplement, and submitted microarray data GSE85987), perhaps by facilitating the activation of the enhancer region associated with the CCL2 transcriptional start site ( Figures 5E and 6B) . Because many enhancers regulate cognate genes over considerable distances, 55 target gene(s) of a given enhancer cannot be accurately predicted simply by genomic distance. To date, no studies have reported chromosome conformation data from inflammatory activated HUVECs, making it difficult to make valid predictions of chromatin folding. To promote a better understanding of how NOTCH1 controls the expression of inflammatory genes in HUVECs, it is, therefore, crucial that future experimental approaches are designed to map the 3-dimensional chromatin structure in relation to RBPJ-NOTCH1-binding sites in the context of inflammatory activation.
Emerging evidence adds support to the notion that cell fate-regulating transcription factors other than the NOTCH1 transcription complex also modulate chromatin at inflammatory enhancers. Illustrating this, lineage-specific expression of stress-inducible target genes of NF-κB, AP-1, and IRF1 (interferon-responsive protein 1) in monocytes/macrophages are programmed by the cell fate-regulating transcription factor PU.1 in synergy with C/EBPα. 56, 57 In a complementary manner, our findings demonstrate that the Notch signaling system dynamically modulates the responsiveness of endothelial cells to proinflammatory cytokine activation.
A fascinating aspect of Notch signaling is the relative contribution of individual Notch ligands to receptor activation. Ligand-specific biological outcomes seem to depend on differences in signal strength and have been demonstrated in inner ear development, 58 T cell differentiation, 59 and during angiogenesis where endothelial JAG1 acts as a competitive antagonist to DLL4. 20 The selective responsiveness of JAG1 to proinflammatory endothelial activation motivated our initial transcriptional screen of the response to JAG1 knockdown, showing a profound effect of JAG1 on endothelial activation. However, subsequent, unpublished experiments in mice with endothelial cell-specific deletion of Jag1 failed to show significant effects on inflammation in the dinitrofluorobenzene-induced contact hypersensitivity model (Edelmann et al, unpublished data, 2012). In contrast, endothelial loss of the canonical Notch transcription factor Rbpj markedly reduced inflammation, suggesting that signaling by other endothelial Notch ligands or ligands expressed by cell types other than endothelial cells promoted inflammatory activation in this model. Supporting the concept that several Notch ligands can drive the proinflammatory effect of NOTCH1, we found that knockdown of either JAG1 or DLL4 in confluent endothelial cell cultures inhibited VCAM1 expression in a similar manner, despite the dramatic increase in JAG1 levels during the time period investigated. Notably, we did not observe any evidence of increased NOTCH1 activity in IL-1β-stimulated cells, despite the upregulation of JAG1 expression. It is, therefore, tempting to speculate that the upregulation of JAG1 by proinflammatory cytokines at least partly serves to compensate for the downregulation of other more potent Notch ligands, like DLL4. Moreover, the ability of individual Notch ligands to induce or inhibit signaling will vary according to the presence of other Notch ligands, 58 the cis-and transexpression of Notch receptors, 60 and the glycosylation status of these receptors. 20 The functional impact of JAG1 induction in a physiological setting, therefore, remains unsettled but invites further investigation.
Although this study was focused on understanding the role of NOTCH1 signaling in endothelial cell activation, assessment of global Notch inhibition as a treatment modality in inflammatory disease may be of even greater therapeutic interest. To this end, the currently most impressive demonstration of Notch involvement in an inflammatory context is perhaps the observation that inhibition of selected Notch ligands controls murine graft-versus-host disease with no overt side effects. 8 We, therefore, propose that the relative contribution of individual Notch components to different inflammatory processes is highly deserving of future exploration. To this end, it will be interesting to systematically assess how Notch ligands and receptors contribute to chronic inflammatory diseases and to what extent components of the Notch pathway are suitable for therapeutic targeting.
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